Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2014; 20(45): 17155-17162
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17155
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17155
Figure 2 Percentage of patients.
A: Percentage of patients achieving a clinical response after the Granulo-Monocyto Apheresis cycle and at 6 mo of follow-up; B: Percentage of patients with intolerance, resistance or contraindications to immunosuppressants and/or biologics who achieved a clinical response after the Granulo-Monocyto Apheresis cycle and at 6 mo of follow-up. Patients are classified according to disease severity.
- Citation: De Cassan C, Savarino E, Marson P, Tison T, Hatem G, Sturniolo GC, D’Incà R. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol 2014; 20(45): 17155-17162
- URL: https://www.wjgnet.com/1007-9327/full/v20/i45/17155.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i45.17155